Composition of Australian Influenza Vaccine for the 2011 season

This page contains information on the recommended influenza vaccine for the Southern Hemisphere winter 2011.

In this section:

Communicable Diseases Surveillance

The Australian Influenza Vaccine Committee (AIVC) met on 6 October 2010, and agreed to adopt the September WHO recommendations.

The Committee decided that the influenza vaccine components for the 2011 season should contain the following:

A (H1N1): an A/California/7/2009 (H1N1) - like strain, 15 µg HA per dose
A (H3N2): an A/Perth/16/2009 (H3N2) - like strain, 15 µg HA per dose
B: a B/Brisbane/60/2008 - like strain, 15 µg HA per dose

Reassortants, vaccine strains and reagents

The TGA considers the following available reassortants or viruses are suitable vaccine strains:

H1N1

NYMC X-179A egg or cell, NYMC X-181, NYMC X-181A, NIBRG-121, NIBRG-121xp reassortants derived from A/California/7/2009.

NIBRG-122 reassortant derived from A/England/195/2009.

IVR-158 reassortant derived from A/Brisbane/10/2010

H3N2

A/Wisconsin/15/2009 and A/Victoria/210/2009 are Perth/16/2009-like viruses

NYMC X-183 reassortant derived from A/Wisconsin/15/2009;

NYMC X-187, NIB-65, IVR-155 reassortants derived from A/Victoria/210/2009

B

B/Brisbane/60/2008; NYMC BX-31, NYMC BX-35, NIB-65 reassortants derived from B/Brisbane/60/2008;

B/Brisbane/33/2008.

If other reassortants or viruses become available, their suitability for use should be discussed with the TGA by emailing influenza.standards@tga.gov.au

For reference antigen and antisera availability, email influenza.standards@tga.gov.au. Please note reagents are also available from NIBSC